Effects of acute and chronic atorvastatin on cardioprotection of ischemic postconditioning in isolated rat hearts

Cardiovascular Therapeutics

Volumn 31, Issue 4, 2013, Pages 187-192

  Fan, Ying ^a   Yang, Shusen ^a   Cao, Yang ^a   Huang, Yonglin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Ischemia reperfusion injury; Ischemic postconditioning; Isolated heart

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ARTICLE; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; ISCHEMIC POSTCONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ATORVASTATIN; ISCHEMIA-REPERFUSION INJURY; ISCHEMIC POSTCONDITIONING; ISOLATED HEART;

ANIMALS; CARDIOTONIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HEMODYNAMICS; HEPTANOIC ACIDS; ISCHEMIC POSTCONDITIONING; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84880667709     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2012.00318.x     Document Type: Article

References (28)

1. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009;73: 1171-1177.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
3. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P. The paradigm of postconditioning to protect the heart. J Cell Mol Med 2008;12: 435-458.
4. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008;117: 1037-1044.
5. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K. 'Postconditioning' the human heart: Multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 2007;102: 274-278.
6. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285: H579-H588.
7. Hausenloy DJ. Signaling pathways in ischaemic postconditioning. Thromb Haemost 2009;101: 626-634.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360: 7-22.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: 1001-1009.
11. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41: 508-515.
12. Kocsis GF, Pipis J, Fekete V, et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008;294: H2406-H2409.
13. Besík J, Szárszoi O, Kunes J, et al. Tolerance to acute ischemia in adult male and female spontaneously hypertensive rats. Physiol Res 2007;56: 267-274.
14. Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 2007;292: H2598-H2606.
15. Szárszoi O, Malý J, Ostádal P, Netuka I, Besík J, Kolár F, Ostádal B. Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol Res 2008;57: 793-796.
16. Gonon AT, Widegren U, Bulhak A, Salehzadeh F, Persson J, Sjöquist PO, Pernow J. Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res 2008;78: 116-122.
17. Jenkins DP, Pugsley WB, Yellon DM. Ischaemic preconditioning in a model of global ischaemia: Infarct size limitation, but no reduction of stunning. J Mol Cell Cardiol 1995;27: 1623-1632.
18. Uematsu M, Okada M. Differences in prolonged ischemia length using ischemic preconditioning in the rabbit heart: Tolerable limitation time for surgically induced myocardial ischemia during normothermic cardiac operation. J Cardiovasc Surg 2001;42: 323-331.
19. Penna C, Cappello S, Mancardi D, et al. Post-conditioning reduces infarct size in the isolated rat heart: Role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 2006;101: 168-179.
20. van Vuuren D, Genis A, Genade S, Lochner A. Postconditioning the isolated working rat heart. Cardiovasc Drugs Ther 2008;22: 391-397.
21. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: Infarct size is a more reliable endpoint than functional recovery. Basic Res Cardiol 2003;98: 337-346.
22. Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006;290: H1960-H1968.
23. Penumathsa SV, Thirunavukkarasu M, Koneru S, et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007;42: 508-516.
24. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66: 462-471.
25. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005;45: 1287-1291.
26. Chen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 2009;104: 496-505.
27. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006;114: 2655-2662.
28. Young LH, Li J, Baron SJ, Russell RR. AMP-activated protein kinase: A key stress signaling pathway in the heart. Trends Cardiovasc Med 2005;15: 110-118.